CYP19A1 and breast carcinoma: The selective estrogen receptor (SERM) antagonist tamoxifen and, more recently, the aromatase inhibitors (AIS) anastrozole, exemestane, and letrozole have all been used as adjuvant endocrine therapy agents for the treatment of hormone receptor–positive early breast cancer.